Cui, Ang http://orcid.org/0000-0002-1087-8568
Huang, Teddy
Li, Shuqiang http://orcid.org/0000-0001-9106-6141
Ma, Aileen http://orcid.org/0000-0002-8665-8772
PĂ©rez, Jorge L. http://orcid.org/0000-0003-3119-1359
Sander, Chris http://orcid.org/0000-0001-6059-6270
Keskin, Derin B.
Wu, Catherine J. http://orcid.org/0000-0002-3348-5054
Fraenkel, Ernest http://orcid.org/0000-0001-9249-8181
Hacohen, Nir http://orcid.org/0000-0002-2349-2656
Article History
Received: 19 May 2021
Accepted: 1 November 2023
First Online: 6 December 2023
Competing interests
: N.H. and C.J.W. hold equity in BioNTech. N.H. is an advisor for Related Sciences/Danger Bio, Repertoire Immune Medicines and CytoReason. A.C. was a consultant for Foresite Capital and Altimmune for unrelated work. D.B.K is a scientific advisor for Immunitrack and Breakbio. DBK owns equity in Affimed N.V., Agenus, Armata Pharmaceuticals, Breakbio, BioMarin Pharmaceutical, Celldex Therapeutics, Editas Medicine, Gilead Sciences, Immunitybio and Lexicon Pharmaceuticals. BeiGene, a Chinese biotechnology company, supports unrelated research at the Translational Immunogenomics Lab. The remaining authors declare no competing interests. N.H. and A.C. have filed patent applications related to this work.